Setting Standards with New Generation Therapies! The ITM Group provides a new generation of highly effective radioisotope therapies and integrated application systems to those oncological and endovascular patients who are currently very difficult or impossible to treat with conventional methods:

• Skin cancer patients with large and difficult to treat lesions (leading to disfiguring, expensive, repeated surgery)
• Diabetic patients with progressed peripheral endovascular disease (generally leading to amputations),
• Cardiovascular patients with recurring in-stent restenosis (leading to infarction).

Through the development of integrated, proprietary application systems and controlling the supply processes from radioisotope production and logistics to patient administration, new levels in radiation safety, convenience, service and efficiency in these radiopharmaceutical and Brachytherapy applications are attained and brought to the clinical environment.

The combination of superior medical effectiveness in patients with otherwise exhausted alternative treatment options and vertical integration along the radiopharmaceutical value chain therefore enables ITM to close therapeutic gaps and provide solutions, products and services to the medical community in sizeable, high value niche applications.

"What we do today was considered impossible 5 years ago ..."